Rytelo (imetelstat) / Geron 
Welcome,         Profile    Billing    Logout  
 144 Diseases   5 Trials   5 Trials   837 News 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rytelo (imetelstat) / Geron
IMpactMF, NCT04576156 / 2020-003288-24: A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Calendar Jan 2025 - Dec 2025: Final analysis data from IMpactMF trial for refractory myelofibrosis
Calendar Jan 2024 - Dec 2024: Interim analysis data from IMpactMF trial for refractory myelofibrosis
Checkmark Trial updates from IMpactMF trial for relapsed/refractory myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Trial updates from IMpactMF trial for relapsed/refractory myelofibrosis at ASH 2022
Recruiting
3
320
Europe, US, RoW
Imetelstat, GRN163L, Best Available Therapy (BAT)
Geron Corporation
Myelofibrosis
11/26
11/26
IMerge, NCT02598661 / 2015-002874-19: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Jan 2023 - Jun 2023: Anticipated NDA Submission for lower risk MDS based on IMerge trial
Checkmark Topline data from P3 IMERGE trial for lower risk MDS
Jan 2023 - Jan 2023: Topline data from P3 IMERGE trial for lower risk MDS
Checkmark Top-line data from IMerge trial for lower risk MDS
Jan 2023 - Jan 2023: Top-line data from IMerge trial for lower risk MDS
More
Active, not recruiting
2/3
289
Europe, Canada, US, RoW
Imetelstat, GRN163L, Placebo
Geron Corporation
Myelodysplastic Syndromes
10/23
10/26
IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Recruiting
2
46
Europe, RoW
Imetelstat sodium, GRN163L
GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group
Myelodysplastic Syndromes, Acute Myeloid Leukemia
02/25
06/26
NCT06247787: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recruiting
1
36
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Echocardiography, EC, Fludarabine, Fluradosa, Hydrocortisone Sodium Succinate, (11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt, A-Hydrocort, Buccalsone, Corlan, Cortisol Sodium Succinate, Cortop, Efcortelan, Emergent-EZ, Flebocortid, Hidroc Clora, Hycorace, Hydro-Adreson, Hydrocort, Hydrocortisone 21-Sodium Succinate, Hydrocortisone Na Succinate, Kinogen, Nordicort, Nositrol, Sinsurrene, Sodium hydrocortisone succinate, Solu-Cortef, Solu-Glyc, Imetelstat, GRN 163L, GRN-163L, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Lumbar Puncture, LP, Spinal Tap, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039
Children's Oncology Group, Geron Corporation, National Cancer Institute (NCI)
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
06/26
06/26
IMproveMF, NCT05371964: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Checkmark Trial updates from IMPROVEMF trial in combination with ruxolitinib in 1L myelofibrosis
Dec 2022 - Dec 2022: Trial updates from IMPROVEMF trial in combination with ruxolitinib in 1L myelofibrosis
Recruiting
1
41
US
Imetelstat, GRN163L, Ruxolitinib
Geron Corporation
Myelofibrosis
02/26
08/27
NCT05937568: Expanded Access for Treatment With Imetelstat

Approved for marketing
N/A
NA
Imetelstat
Geron Corporation
Myelodysplastic Syndromes
 
 

Download Options